Jazz Pharmaceuticals (JAZZ)
(Real Time Quote from BATS)
$136.15 USD
+1.90 (1.42%)
Updated Oct 17, 2025 03:36 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Jazz Pharmaceuticals PLC has a PEG ratio of 2.12 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.77.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JAZZ 136.15 +1.90(1.42%)
Will JAZZ be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why JAZZ Stock Is an Unconventional Cannabis Investment
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Other News for JAZZ
3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street
First Week of June 2026 Options Trading For Jazz Pharmaceuticals (JAZZ)
JAZZ falls 1.14% on October 16, leaving the technical picture intact
Jazz Pharmaceuticals Completes Study on Promising HER2 Cancer Treatment
Is JAZZ positioned for a breakout? 20 Day Moving Average Support shows up after climbing 1.49%